About 26 results found for searched term "Mip-IN-1" (0.121 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M15026 | Recombinant Human MIP-1β /CCL4 (E. coli) | Cytokines and Growth Factors |
| MIP-1 beta; Macrophage Inflammatory Protein-1β; CCL-4; ACT-2 | ||
| Macrophage inflammatory protein 1β (MIP-1β), also known as Chemokine (C-motif) ligand 4 (CCL4), is a small cytokine in the CC Chemokine family. It is a chemical attractant for natural killer cells, monocytes and a variety of other immune cells. Protein structure: MIP-1β (ALA24-ASN92), Accession # P13236-1. | ||
| M14561 | Recombinant Human MIP-5/CCL15 Protein (E. coli, aa 22-113, C-His) | Cytokines and Growth Factors |
| SCYA15; HCC-2; NCC-3 | ||
| Chemokine ligand 15 (CCL15), also known as leukotactin-1, MIP5, MIP1 and HCC-2, is a small cytokine belonging to the C-C chemokine family. CCL15 is prevantly expressed in liver, small intestine, colon, and in certain leukocytes and macrophages of the lung. | ||
| M42977 | Mip-IN-1 | Others |
| Mip-IN-1（S,S-28i）is a new rapamycin-derived macrophage infectivity potentiator (Mip) inhibitor. | ||
| M55629 | MIPS-21335 | PI3K |
| MIPS21335 | ||
| MIPS-21335 is a PI3KC2α inhibitor, with IC50 of 7 nM. MIPS-21335 also inhibits PI3KC2β, p110α, p110β and p110δ with IC50 values of 0.043, 0.140, 0.386, 0.742 μM, respectively. | ||
| M1559 | Clomipramine Hydrochloride | 5-HT Receptor |
| Clomipramine HCl is a hydrochloride salt of clomipramine which is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively. | ||
| M5923 | Rebamipide | COX |
| OPC-12759 | ||
| Rebamipide (OPC12759) is a cholecystokinin-1 (CCK1) receptor inhibitor that inhibits [125I]BH-CCK-8S with an IC50 of 37.7 μM. Rebamipide is an orally effective gastroprotective agent. Rebamipide enhances the production of endogenous PGs (particularly intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide also has anti-proliferative activity against gastric cancer cells. | ||
| M9525 | Pamiparib | PARP |
| BGB-290 | ||
| Pamiparib (BGB-290) is an orally active, potent, highly selective inhibitor of PARP1 and PARP2 with IC50 values of 0.9 nM and 0.5 nM, respectively. | ||
| M13379 | Guggulsterone | Apoptosis |
| Z/E-Guggulsterone | ||
| Guggulsterone is a plant sterol from the gum fat of the Commiphora Wightii tree. Guggulsterone is a farnesoid X receptor (FXR) antagonist, decreases CDCA-induced FXR activation with IC50s of 17 and 15 μM for Z- and E-Guggulsterone, respectively. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt. | ||
| M15025 | Recombinant Mouse MIP-1α/CCL3 (HEK 293) | Cytokines and Growth Factors |
| Macrophage Inflammatory Protein-1α; CCL-3; LD78α; LD78 alpha | ||
| MIP-1 Alpha, also known as CCL3, G0S19-1 and SCYA3, LD78 Alpha, is an inflammatory chemokine. Mip-1 α belongs to the CCL chemokine family and has 68% homology with MIP-1β. The mature form of MIP-1α contains 69 amino acids, which are present in solution as dimers and tend to accumulate reversibly. Protein structure: MIP-1α (ALA24-ALA92), Accession # : Q5QNW0. | ||
| M15024 | Recombinant Human MIP-1α/CCL3 (CHO) | Cytokines and Growth Factors |
| Macrophage Inflammatory Protein-1α; CCL-3; LD78α; LD78 alpha | ||
| Mip-1 Alpha, also known as CCL3, G0S19-1 and SCYA3, LD78 Alpha, is an inflammatory chemokine. Mip-1 α belongs to the CCL chemokine family and has 68% homology with MIP-1β. The mature form of MIP-1α contains 69 amino acids, which are present in solution as dimers and tend to accumulate reversibly. Protein structure: MIP-1α (ALA27-ALA92), Accession # : P10147. | ||
| M15054 | Recombinant Mouse DCIP-1/CXCL3 (CHO) | Cytokines and Growth Factors |
| C-X-C motif chemokine 3; Dendritic cell inflammatory protein 1 | ||
| Chemokine (C-X-C Motif) ligand 3 (CXCL3) is a small cytokine in the CXC chemokine family, also known as DCIP-1(Dendritic cell inflammatory protein-1) or MIP-2B. Protein structure: CXCL3 (ALA28-SER100), Accession # : Q6W5C0. | ||
| M13927 | TAK-220 | CCR |
| TAK-220 is a selective and orally bioavailable CCR5 antagonist, with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA). | ||
| M15055 | Recombinant Mouse CXCL3 (E. coli, His Tag) | Cytokines and Growth Factors |
| C-X-C motif chemokine 3; Dendritic cell inflammatory protein 1; DCIP-1 | ||
| Dendritic cell inflammatory protein-1 (DCIP-1)/CXCL3 is also known as MIP2β(macrophage inflammatory protein 2 beta) or DCIP1(Dendritic cell inflammatory protein 1) in mice and CINC2(cytodynamics-induced neutrophil attractant 2) in rats, In humans it is known as GRO gamma (Growth regulated oncogene gamma). | ||
| M15101 | Cemiplimab | PD-1/PD-L1 |
| Libtayo; REGN-2810; cemiplimab-rwlc | ||
| Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Cemiplimab blocks T-cell inactivation and boosts the immune system's antitumor response. | ||
| M18469 | Flemiphilippinin D | IDO |
| Kushenol E | ||
| Flemiphilippinin D (Kushenol E) is a non-competitive indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC50 of 7.7 µM and a Ki of 9.5 µM. Flemiphilippinin D (Kushenol E) is a flavonoid isolated from Sophora flavescens, it has anti-tumor activity. | ||
| M19980 | Recombinant Mouse MIP-3α/CCL20 (E. coli) | Cytokines and Growth Factors |
| CCL-20; CKb4; Exodus; LARC; MIP-3-alpha | ||
| Macrophage Inflammatory Protein-3 (MIP-3α), also known as chemokine (C-C motif) ligand 20 (CCL20) or liver activation regulated chemokine (LARC), is a small cytokine belonging to the CC chemokine family. Determined by a chemotaxis bioassay using human CCR6 transfected murine BaF3 cells, the biologically active is in a concentration range of 0.1-10.0 ng/ml. | ||
| M19981 | Recombinant Rat MIP-3 α/CCL20 (HEK 293) | Cytokines and Growth Factors |
| CCL-20; CKb4; Exodus; LARC; MIP-3-alpha | ||
| Macrophage inflammatory protein-3 (MIP-3α), also known as chemokine (C-C motif) ligand 20 (CCL20) or liver activation regulated chemokine (LARC), is a small cytokine in the CC chemokine family. Accession P97884 - # 1. | ||
| M20874 | Elamipretide | Mitochondrial Related |
| MTP-131; D-Arg-Dmt-Lys-Phe-NH2; SS-31; RX-31 | ||
| Elamipretide (MTP-131, SS-31, D-Arg-Dmt-Lys-Phe-NH2) is a cytochrome c peroxidase inhibitor. Elamipretide (MTP-131) is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury. Elamipretide improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. | ||
| M21181 | Zetomipzomib | Proteasome |
| KZR-616 | ||
| Zetomipzomib (KZR-616) is the first immunoproteasome inhibitor that selectively targets the immunoproteasome subunits LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7). Zetomipzomib has potential for use in a variety of autoimmune diseases. | ||
| M21515 | Zetomipzomib maleate | Proteasome |
| KZR-616 maleate | ||
| Zetomipzomib (KZR-616) maleate is a first-in-class inhibitor of immunoproteasome that selectively targets the immunoproteasome subunit LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50:131/179 nM=hLMP7/mLMP7). Potential of Zetomipzomib maleate for use in multiple autoimmune diseases. | ||
| M24740 | Mipeginterferon alfa-2b | Others |
| Mipeginterferon alfa-2b is an interferon alpha-2b (IFNA2b) analogue, with an average number of 5 substituted among 11 amino groups (one N-terminal and 10 lysine N6). Mipeginterferon alfa-2b has the relative molecular mass of 40 kDa. | ||
| M25072 | Mipasetamab uzoptirine | TAM Receptor |
| ADCT-601 | ||
| Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers. | ||
| M25091 | Mipasetamab | Others |
| Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity. | ||
| M28890 | WCK-4234 | Antibiotic |
| WCK-4234 is a potent β-lactamase inhibitor. WCK-4234 inhibits class A, C, and D β-lactamases activity. WCK-4234 lacks direct antibacterial activity. WCK-4234 potentiates imipenem and meropenem against Enterobacteriaceae with OXA-48/OXA-181 or KPC enzymes, or with combinations of impermeability and AmpC or ESBL activity. WCK-4234 distinctively overcomes resistance mediated by OXA-type carbapenemases. | ||
| M30561 | Trimipramine | 5-HT Receptor |
| Trimipramine is a 5-HT receptor antagonist, with pKi binding values of 6.39, 8.10, 4.66 for 5-HT1C, 5-HT2 and 5-HT1A, respectively. Trimipramine is also a potent and selective inhibitor targeting human noradrenaline (hNAT), serotonin (hSERT) and organic cation transporters (hOCT1, hOCT2) with IC50 values of 4.99 μM, 2.11 μM, 3.72 μM, 8.00 μM, respectively. Trimipramine has vascular activity and anxiolytic efficacy. | ||
| M56156 | trans-J-113863 | CCR |
| trans-J-113863 is a potent chemokine CCR1 and CCR3 receptor antagonist, and inhibits MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants with IC50 of 9.57 and 93.8 nM,respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
